Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 160

Results For "RAT"

10033 News Found

Cipla launches India's first sputum inflammometry lab in Mumbai
Healthcare | June 03, 2026

Cipla launches India's first sputum inflammometry lab in Mumbai

The facility sets a new benchmark in respiratory diagnostics


Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350
News | June 03, 2026

Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350

DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability


CARE Hospitals strengthens advanced cardiac care
Hospitals | June 03, 2026

CARE Hospitals strengthens advanced cardiac care

The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries


Akums secures European CEP approval for Cefpodoxime Proxetil
Drug Approval | June 03, 2026

Akums secures European CEP approval for Cefpodoxime Proxetil

The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner


FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care
Drug Approval | June 03, 2026

FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care

The filing is backed by Phase III data from the lidERA Breast Cancer study


Lupin and Natco get FDA approval for Eribulin Mesylate injection
Drug Approval | June 03, 2026

Lupin and Natco get FDA approval for Eribulin Mesylate injection

Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.


Servier to acquire Edgewise muscular dystrophy business in $2.65 billion deal
News | June 03, 2026

Servier to acquire Edgewise muscular dystrophy business in $2.65 billion deal

The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments


Omnix Medical doses first patients in phase II trial of antimicrobial lead compound OMN6
News | June 03, 2026

Omnix Medical doses first patients in phase II trial of antimicrobial lead compound OMN6

First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept


Granules Pharmaceuticals receives USFDA EIR for Chantilly facility
News | June 03, 2026

Granules Pharmaceuticals receives USFDA EIR for Chantilly facility

This facility plays an important role in Granules’ global manufacturing and supply network